Catalent has agreed to acquire Accucaps Industries Limited, an Ontario, Canada-based developer and manufacturer of over-the-counter (OTC), high potency, and conventional pharmaceutical softgels. Financial details of the transaction were not disclosed.

The acquisition, which is subject to Canadian governmental approval, boosts Catalent’s OTC and prescription pharmaceutical softgel capabilities and capacity with the addition of a portfolio of products supplied to pharmaceutical companies in North America and two facilities offering softgel development, manufacturing, and packaging.

Upon completion of the acquisition, Accucaps’ more than 500 employees at its two facilities in Windsor and Strathroy, Ontario, will join Catalent’s global network of 11 softgel technologies facilities. The Accucaps facilities feature blistering, bottling, and other packaging capabilities as well as high-potency prescription softgel development and manufacturing expertise.

Source: Catalent